To order sections of the reports, contact Client Services.

This report is designed to provide the in vitro diagnostics industry executives with strategically significant competitor information, analysis and insight crucial to the development and implementation of effective business, marketing and R&D programs. The study’s major objectives include:

• To establish a comprehensive, factual, annually updated and cost-effective information base on performance, capabilities, goals and strategies of the world’s leading in vitro diagnostics companies....
  

Introduction

The financial crisis has wrought significant changes in the Wealth Management Super League, with dramatic shifts in the rankings that existed pre-financial crisis. Here, Datamonitor puts the world's largest wealth mangers under the microscope to examine their recent performance, as well as their future outlook....

- Will the industry consolidate, decentralize, or undergo a bimodal transformation

- What will be the impact on purchasing influences, marketing strategies, joint ventures, mergers, licensing, import and export

- How will the future technological advances affect the major market segments

- Which companies will enter the market and which will not survive

Reimbursement of the diagnostic testing is the key issue for both the providers and the payers. While only 5-7% of the hospital expenditures are attributed to laboratory testing, the test results are used in 70% of the healthcare decisions....

This report provides an overview of current developments in integrated medical diagnostics, covering the emergence of new methods that combine IVD with current and developing imaging platforms. The drivers of this integration are reviewed, including new disease biomarkers; single, combined and emerging imaging systems; as well as IT and patient-centred systems....

The medical device industry is highly regulated in the US and EU and is driven by innovation and technological expansion. The level of mergers and acquisitions is high, with a total of 171 deals in 2010....

This report examines the various models that are being adopted by players and uses case studies to highlight the risks and rewards of different approaches to partnerships. The challenges facing companies when entering into a collaboration and factors that should be taken into account when selecting a partner are reviewed and recommendations given as to best practices in partnering.

• Five-year U.S....
  

• Review of major product lines.
• Specifications, features, advantages, weaknesses, introduction dates and prices of current analyzers, reagent systems and ancillary products....
  

Well-implemented CSR can facilitate highly beneficial outcomes for companies, but is difficult to get right. Effective message framing is as important as the actions embodying the CSR ethos, especially when deep-rooted skepticism equates to less than 20% of consumers expressing high trust in business to do what is right across a range of CSR issues. Overall, CSR sincerity is in question

• Five-year reagent and instrument sales forecasts for major testing locations (hospitals, commercial/private laboratories, physician offices/group practices, blood center, personal testing and others and major laboratory disciplines (blood typing/grouping, chemist/immunoassay, coagulation, hematology/flow cytometry, histology/cytology, microbiology/serology, urinalysis and others).
• Five-year worldwide sales projections for the most dynamic market segments, such as molecular diagnostics, infectious diseases, tumor markers, and personal testing are developed....
  

• Business, new product development, and marketing strategies.
• Anticipated acquisitions, joint ventures, and divestitures....
  

• The U.S....
  

• Major joint venture, distribution, O.E....
  

• History of the diagnostics business evolution important to the understanding of the company’s culture management mentality and strategies.
• Most recent significant acquisitions, divestitures and organizational changes....